Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
January 31 2022 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today released its inaugural
environmental social and governance (ESG) report highlighting
Twist’s approach to sustainability, social responsibility and
commitment to ethics. The full report is available to view at
https://www.twistbioscience.com/company/esg.
“We are proud to share the results of our ESG report, which
reflects the ongoing work since our founding that demonstrates our
commitment to ethical practices, recruiting and developing a
diverse global workforce, and fostering a corporate culture where
employees feel valued, respected and have a sense of belonging,”
said Angela Bitting, SVP, corporate affairs and chief ESG officer
for Twist Bioscience.
“Our commitment to writing the future of sustainability begins
with the reduced chemical footprint of our silicon-based synthetic
DNA platform and enables our customers to more sustainably develop
therapeutics, diagnostic tests, agriculture yields, and so much
more,” continued Bitting.
Commitment to a Diverse Workforce
Twist employs a diverse workforce and as of December 2020, 63%
of Twist’s workforce1 was made up of people of color, with women of
color making up 27% of the organization. Women make up 39% of the
global workforce at Twist and are well represented in leadership
positions, accounting for 42% of the executive team and 30% of the
Board of Directors. Twist is committed to continuing to increase
diversity in its growing workforce over the long term, with the
short-term goal of increasing the percentage of women and racial
diversity by 3% by the end of 2022, as compared to the end of 2021.
To support diversity in recruiting and inform strong biotech
curricula, the company is partnered with California Community
Colleges and educational initiatives aimed at training the next
generation of biomanufacturers.
In addition to providing flexible work arrangements to
employees, Twist has several programs in place to encourage career
growth and development, including internal leadership programs,
specialized trainings, an online learning platform and tuition
reimbursement of up to $5,250 per year. Twist also encourages
employees to participate in philanthropic initiatives and provides
8 hours of paid time off per year for volunteer efforts.
Sustainable Platform and Practices
Twist’s silicon-based synthetic DNA platform offers a more
sustainable alternative to legacy methods by miniaturizing the
chemical reaction. Twist’s silicon chip has the same footprint as
the 96-well plate used in traditional DNA synthesis approaches but
contains millions of nanometer-scale devices, allowing Twist to
synthesize over one million oligos at once, compared to 96 oligos
generated by other approaches. Twist’s approach uses 99.8% less
reagent per gene and does not produce excess oligo, completely
removing oligo waste from the gene synthesis process.
As part of Twist’s commitment to sustainability beyond its
platform, the company has implemented internal recycling programs,
including a plastic glove recycling initiative that has diverted
over 11 thousand pounds of plastic waste from landfills.
Ethical Practices Across the Organization
Twist has a comprehensive privacy policy in place and has
obtained a certificate for the highest level of information
security recognized by the International Organization for
Standardization (ISO). The company also works with governments as
well as other DNA synthesis providers to develop, promote and
evolve a consistent set of biosecurity best practices.
Twist performs rigorous biosecurity and export control screening
to ensure that sequences of DNA that could pose significant risk if
misused are not synthesized and shipped to unlicensed
organizations. The same high ethical standards are applied across
the organization and include meticulous record keeping, reporting
and allocation of personnel resources to ensure that employees
follow set policies and procedures.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn |
YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report Form 10-K
filed with the Securities and Exchange Commission on November 23,
2021 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
1 Employee base
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220131005298/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 abittingS@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024